Gilead Sciences Inc.’s remdesivir was given an emergency use approval on Friday 1 May by the US Food and Drug Administration, the first drug to show benefits to patients with COVID-19 and a major step forward in tackling the pandemic.
The approval was based on results from the ACTT adaptive trial released on 29 April which showed that the antiviral...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?